Company intelligence / Profile preview

Inhibrx

La Jolla, California, United Statesinhibrx.com ↗

Ownership: Public · INBX
Development stage: Phase 2

Overview

Ozekibart (INBRX-109) showed promising results in colorectal adenocarcinoma with one complete response, three partial responses, and six cases of stable disease in a Phase 1 trial. Durable disease control lasting ≥180 days was observed in 46.2% of patients, with a median progression-free survival of 7.85 months. The company is conducting a registration-enabling Phase 2 trial for ozekibart in unresectable or metastatic conventional chondrosarcoma.

Therapeutic areas: OncologyRare Diseases
Modalities: Protein therapeuticsBiologic therapeuticsSingle-domain antibody platform
Industry: Biotech

Drug pipeline

6 assets

inbrx-106

5 more assets in the full pipeline.

Request access →

Partnerships

Sanofi

Financials

Market cap: $1.7B
Total revenue: $0
Enterprise value: $1.5B

Beyond the preview

Go deeper on Inhibrx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inhibrx.

Explore the full profile